Monrol Announced Investment to Increase Production Capacity for Lu-177 n.c.a.

Eczacıbaşı Monrol Nuclear Products Co. (Monrol, Turkey) has decided to invest €35 million to increase its production capacity for Lutetium-177 n.c.a. in response to growing global demand for this product.

The expansion project will be phased in and will reach full capacity by 2026.

Lu-177 is widely used for targeted radioligand therapy in the treatment of prostate cancer and neuroendocrine tumors and expected to be used to treat other cancers in future.

To read more please visit:

Monrol Announced Investment to Increase Production Capacity for Lu-177 n.e.c.

Source: Businesswire